Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 13/20 | 0.55 |
| ▸ | GAA | P10253 | 13/20 | 0.55 |
| ▸ | SI | P14410 | 13/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 13/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | HAT1 | O14929 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KIF20A | O95235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218993 | 0.90 | MGAM (0.55) | MGAMGAASIMGAM2PNP | |
| SCHEMBL3229458 | 0.87 | MGAM (0.50) | MGAMGAASIMGAM2HAT1 | |
| SCHEMBL15709191 | 0.85 | MGAM (0.64) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL15731796 | 0.85 | MGAM (0.64) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL30919353 | 0.85 | MGAM (0.64) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL15148952 | 0.83 | MGAM (0.76) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL13458820 | 0.82 | MGAM (0.43) | MGAMGAASIMGAM2HAT1 | |
| SCHEMBL3225449 | 0.80 | MEN1 (0.45) | MGAMGAASIMGAM2HAT1 | |
| SCHEMBL3232638 | 0.77 | SLC6A4 (0.72) | MGAMGAASIMGAM2HAT1 | |
| SCHEMBL3231514 | 0.77 | MGAM (0.50) | MGAMGAASIMGAM2HAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | GREENHOUSE ROBERT | 2010-03-04 | — | — | US | disclosed |
| US-7638517-B2 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638517-B2 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1957488-B1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | EP | disclosed |
| CN-101321752-A | 3-amino-2-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1957488-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062998-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007062998-A1 | 3-AMINO-2-ARYLPROPYL AZAINDOLES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123535-A1 | 3-Amino-1-arylpropyl azaindoles and uses thereof | CNKSR1, AR, CYP3A43 | MGAM 3879/4885GAA 3358/4885SI 2178/4885 |
| US-20100056499-A1 | 3-AMINO-1-ARYLPROPYL AZAINDOLES AND USES THEREOF | CNKSR1, AR, CYP3A43 | MGAM 3879/4885GAA 3358/4885SI 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.